You are here

Three Year Follow-Up Data Show Statistically Significant Improvement in Survival for Patients Treated With Ceplene, IL-2 Combination

SAN DIEGO--(BUSINESS WIRE)--June 4, 2004--Maxim Pharmaceuticals, Inc. (Nasdaq:MAXM) (SSE:MAXM) today announced that the 36-month patient follow-up data from the M01 Phase 3 study of Ceplene(TM) (histamine dihydrochloride) as a combination therapy to treat advanced metastatic melanoma has been published electronically in an article by Hellstrand et al, for the June issue of the Journal of Cancer Immunology and Immunotherapy.

The 36-month results demonstrate that the intent-to-treat population of all 305 advanced metastatic melanoma patients randomized into the trial demonstrated a statistically significant improvement in survival for patients treated with the combination of Ceplene and IL-2 (p=0.037, evaluated by comparing Kaplan-Meier survival curves using the log-rank test) compared to patients treated with IL-2 alone. The improvement in three-year survival remained significant in the subpopulation of advanced metastatic melanoma patients with liver metastases (p=0.006).

"We are pleased that the scientific and clinical community continue to recognize the results of our first phase 3 trial in advanced stage IV melanoma. Patients with this rapidly progressive disease today do not have an effective treatment option," said Dr. Kurt R. Gehlsen, Maxim's Chief Scientific Officer. "Our initial phase 3 trial remains the first large randomized clinical trial, for any new treatment, to demonstrate a survival benefit in this patient population."

Ceplene Status
In May 2004, the Company announced the approval of a treatment protocol in the United States allowing the Company to provide the Ceplene combination therapy to malignant melanoma patients under an expanded access program while the current Phase 3 trial is being completed. The Company expects to complete its current Phase 3 trial in melanoma patients with liver metastases this summer and amend its NDA with the results from the current Phase 3 study in late 2004. A centralized application for marketing of Ceplene therapy in malignant melanoma was filed with the European regulatory authorities in November 2003 and is currently under review.

The Company also recently announced completion of a Phase 3 trial in acute myeloid leukemia, in which the combination of Ceplene plus IL-2 significantly improved leukemia free survival, the primary endpoint. The results for the primary endpoint can be see on the company's website at www.maxim.com.

Source: Maxim Pharmaceuticals

More Headlines

Inexpensive, Wearable Therapy Increases Arm Mobility, Reduces Stiffness
Atezolizumab in Combination with Chemotherapy is the Only First-line Cancer Immunotherapy for ES-SCLC
Pre-clinical Trials Showed Drug Inhibits Fibroblast Activity and Collagen Deposition
PARG Inhibitor Exploits Weakness, Kills Cells
National Statistics Report Factors In Race, Ethnicity for the First Time
FDA Prioritizing Review of ARB Applications to Help Mitigate Drug Shortage
California Woman Claimed Asbestos in Talc-Based Powder Caused Her Mesothelioma
Synergistic Effects Seen When Combined With Cisplatin in Mice
For Locally Advanced or Metastatic Triple-Negative Type Only